MedTrace Logo

Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma

NCT07270835 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-12-08

No results posted yet for this study

Summary

For patients who met the inclusion criteria, treatment regimens were administered: Rituximab 375 mg/m², intravenously, once weekly for 4 weeks.

Zanubrutinib 160 mg, orally, twice daily for 4 weeks. Combined drugs: prednisone 100 mg/m²/d, orally, d1-5; Ruxolitinib 15mg bid orally; With/without emapalumab as appropriate.

Conditions

  • Hemophagocytic Lymphohistiocytosis
  • B Cell Lymphoma

Interventions

DRUG

Rituximab

375 mg/m², intravenously, once weekly for 4 weeks

DRUG

Zanubrutinib

160 mg, orally, twice daily for 4 weeks as for rutuximab.

Sponsors & Collaborators

  • The First Affiliated Hospital of Soochow University

    lead OTHER

Principal Investigators

  • Xuefeng He, doctor · department of hematology, The First Affiliated Hospital of Soochow University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
14 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-01
Primary Completion
2027-04-30
Completion
2027-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07270835 on ClinicalTrials.gov